Prolight announces appointment of Professor Matt Reed to Clinical Advisory Board
Prolight Diagnostics announces today that Matt Reed, Professor of Emergency Medicine at Edinburgh University, will join the Clinical Advisory Board of the company. His appointment will bring additional insights into the implementation of point-of-care testing in the Emergency Department setting. “We are delighted to welcome Professor Reed onto our Clinical Advisory Board. It is important […]
Emergers publishes updated analysis for Prolight Diagnostics
Emergers updates analysis of Prolight Diagnostics following positive results from the whole blood study at St Thomas’ Hospital. Read the article here: https://www.emergers.se/prolight-k25/ For further information, please contact:Ulf Bladin, CEOE-mail: info@prolightdx.comPhone: +46 73 582 39 87Company website: www.prolightdx.com About UsProlight Diagnostics AB develops innovative Point-of-Care systems. These are small, portable instruments and disposable cartridges for performing […]
Prolight invites to digital investor meeting due to recent achieved milestones
In connection with the subscription period for Prolight Diagnostics AB’s (Prolight’ or the ‘Company’) rights issue of shares, which runs between June 16 and June 30, 2025, the Company invites shareholders and external investors to a digital investor meeting. The meeting will be held via Microsoft Teams on June 24, 2025, at 14:00 CEST. During […]
Prolight receives notice of allowance in Japan for core patent related to Psyros™ technology
Prolight Diagnostics announces today that the company have received a notice of allowance from the Japanese Patent office for their primary patent application related to the Psyros single-molecule-counting technology. This is the second territory to allow this application, following grant by the European Patent Office earlier this year. “We are delighted to have another territory […]
The subscription period in Prolights rights issue of shares starts today
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE ADDITIONAL REGISTRATION OR OTHER MEASURES. Today, […]
Prolight announces positive data from patient blood study at St Thomas’ Hospital, London
Data from St Thomas’ Hospital have confirmed equivalence between whole blood and plasma from patients with elevated troponin levels. The study is a key stepping-stone between the successful biobank study earlier this year and the planned clinical study for product approval. “These initial results from St Thomas’ Hospital are highly encouraging and exactly what we […]
Prolight publishes information document in connection with rights issue of shares
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE ADDITIONAL REGISTRATION OR OTHER MEASURES. Prolight […]
Extraordinary general meeting of Prolight Diagnostics AB (publ) on 10 June 2025
The extraordinary general meeting (EGM) of Prolight Diagnostics AB (publ) (the “Company”) took place on 10 June 2025 in Lund. The EGM resolved in accordance with the proposals by the board of directors. The main content of the main resolutions is described below. Resolution on approval of the board of directors’ resolution to issue shares […]
The future of Point of Care Analysis – Right Here, Right Now
Prolight Diagnostics has developed a breakthrough point-of-care system that delivers reliable test results in 10 minutes or less, right at the patient´s side. Driving efficiency and accelerating time to clinical decision. Watch the video (https://youtu.be/WVNC8vKRdWA) to discover why our proprietary, patent-protected technology is at the heart of the next major shift in healthcare. For further information, please […]
Prolight announces additional subscription commitments and a lock-up commitment for upcoming rights issue of shares
Prolight Diagnostics (“Prolight” or the “Company”) hereby announces that additional existing shareholders and external investors have submitted subscription commitments totaling 2.9 MSEK for the upcoming rights issue of shares (the “Rights Issue”) that Prolight resolved on, subject to approval by the subsequent extraordinary general meeting, on May 21, 2025. Including these new subscription commitments, the […]
